Sign In
Buy AKBA
$0.97
+0.0333 (+3.56%)
At Close: Jun 03, 2026
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Monday, 01'st Jul 2024
CAMBRIDGE, Mass. , July 1, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, grant
Akebia Therapeutics to Present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference
08:18am, Thursday, 27'th Jun 2024
CAMBRIDGE, Mass. , June 27, 2024 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, to
Akebia Therapeutics Appoints Erik Ostrowski as Chief Financial Officer and Chief Business Officer
08:58am, Monday, 24'th Jun 2024
CAMBRIDGE, Mass. , June 24, 2024 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, to
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Monday, 03'rd Jun 2024
CAMBRIDGE, Mass. , June 3, 2024 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, grante
Akebia Therapeutics to Present at the Jefferies Global Healthcare Conference
08:00am, Thursday, 23'rd May 2024
CAMBRIDGE, Mass. , May 23, 2024 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, t
Akebia Therapeutics to Present at the 2nd Annual HCW Bioconnect Investor Conference
08:00am, Tuesday, 14'th May 2024
CAMBRIDGE, Mass. , May 14, 2024 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, tod
Akebia Therapeutics, Inc. (AKBA) Q1 2024 Earnings Call Transcript
10:54am, Thursday, 09'th May 2024
Akebia Therapeutics, Inc. (NASDAQ:AKBA ) Q1 2024 Earnings Conference Call May 9, 2024 8:00 AM ET Company Participants Mercedes Carrasco - Senior Director, Corporate Communications and IR John Butler -
Akebia Therapeutics (AKBA) Reports Q1 Loss, Misses Revenue Estimates
09:10am, Thursday, 09'th May 2024
Akebia Therapeutics (AKBA) came out with a quarterly loss of $0.09 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.14 per share a year ago.
Akebia Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
07:00am, Thursday, 09'th May 2024
Akebia to host conference call at 8:00 a.m. ET on May 9 Vafseo® (vadadustat) tablets FDA approved on March 27, 2024 Vafseo launch activities underway with availability expected in January 2025 Auryxi
Akebia Therapeutics to Report First Quarter 2024 Financial Results and Discuss Recent Business Highlights
08:30am, Thursday, 02'nd May 2024
Akebia to Host Conference Call on May 9, 2024, at 8:00 a.m. ET CAMBRIDGE, Mass.
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Wednesday, 01'st May 2024
CAMBRIDGE, Mass. , May 1, 2024 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted
Buy Vafseo's Approval: A New Chapter For Akebia Therapeutics In Anemia Management
05:56pm, Thursday, 04'th Apr 2024
Akebia Therapeutics, Inc.'s drug Vadadustat, known as Vafseo, received FDA approval for the treatment of anemia in adults on dialysis, offering improved anemia management for a large patient populatio
Akebia Therapeutics Surges on FDA Approval for Anemia Treatment
09:11am, Wednesday, 03'rd Apr 2024
Akebia Therapeutics Inc. NASDAQ: AKBA is a biopharmaceutical company specializing in developing treatments for chronic kidney diseases (CKD) and anemia management for patients with CKD. The medical se
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Tuesday, 02'nd Apr 2024
CAMBRIDGE, Mass. , April 2, 2024 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, grant
Akebia (AKBA) Up as Vafseo Gets FDA Nod for Anemia Due to CKD
08:11am, Thursday, 28'th Mar 2024
Akebia (AKBA) gains during premarket hours on Mar 28 as its key product Vafseo (vadadustat) tablets receive FDA's approval for the treatment of anemia due to chronic kidney disease.
